INTRODUCTION
A universal vaccine against influenza virus remains elusive. Although the induction of broadly neutralizing antibodies to influenza virus shows promise, 1 cross-protective T-cell immunity will likely be an important component of any broadly protective long-lasting vaccine. T-cell epitopes are highly conserved in diverse influenza strains. 2 However, even a live influenza infection only transiently boosts circulating T-cell responses in previously immune adults. 3, 4 Moreover, older people have impaired immunity to influenza and are highly vulnerable to influenza-induced morbidity and mortality. 5 Therefore, we need a means of inducing long-lived protective immunity that could be administered in midlife to allow protection late in life.
Tissue-resident memory T cells (Trm) reside in tissue to provide a first line of defense against recurrent infection. 6, 7 Trm are induced when T cells enter the infected tissue during primary infection and differentiate in situ to form a noncirculating population that can persist to rapidly respond upon re-exposure to antigen. 6, 7 Within the lung, CD8 Trm have been shown to mediate protective heterotypic immunity to influenza infection. 8, 9 However, longevity is a problem as lung CD8 Trm disappear within months after influenza infection, and heterotypic immunity is lost despite steady numbers of memory CD8 T cells in the spleen and circulation that can still traffic into the lung tissue. 8, 10, 11 CD137 (4-1BB) signals are particularly potent in enhancing the expansion and maintenance of CD8 effector and memory T cells. 12 Moreover, lack of 4-1BBL impairs the recall response to influenza virus, 13 attributed to a loss of effector memory T cells at the late stage of the primary response.
14 However, to date, the effect of 4-1BBL on tissue-resident memory T cells has not been examined.
Most individuals receive influenza vaccines in adulthood after previous exposure to natural influenza infection. Therefore, to mimic the effect of vaccination of a previously immune adult, we asked whether boosting with influenza nucleoprotein (NP) together with 4-1BBL improves the duration of protection to influenza virus. We show that intranasal (i.n.) immunization of influenza-immune mice with a replication-defective adenovirus containing influenza NP and 4-1BBL results in induction of a long-lived circulating memory population of effector memory T cells (Tem) as well as a substantial Trm population in the lung that protects mice against lethal heterotypic influenza challenge into old age (1-year-old). These effects require 4-1BB on the CD8 T cells. Remarkably, in mixed bone marrow chimeras 4-1BB-deficient T cells are almost completely absent from the lung parenchymal pool of memory CD8 T cells established during primary influenza infection. These findings establish an essential role for 4-1BB/4-1BBL interactions in the formation of persistent CD8 Trm within the lung during influenza infection.
RESULTS

Local stimulation of 4-1BB in a secondary immunization augments the number of circulating memory CD8 T cells and provides long-lived protection against lethal influenza challenge
Intranasal administration of a replication-defective adenovirus containing the influenza NP gene and 4-1BBL (Ad-NP-4-1BBL) can lower the required vaccine dose for induction of NP 366-374 -specific CD8 T cells that is protective against lethal influenza challenge compared with a vaccine containing NP (Ad-NP) alone. 15 However, this effect is short lived, providing protection for only an additional 3 months over NP alone. 15 Moreover, studies of T-cell responses during the 2009 pandemic showed that even a live infection induces only transient boosting of circulating pre-existing CD8 memory populations in humans. 3, 4 Thus, there is a need to improve upon even the natural infection to obtain long-term robust T-cell immunity to influenza virus. As 4-1BB stimulation is more effective in a secondary as compared with a primary CD8 T-cell response, [16] [17] [18] we asked whether delivery of 4-1BBL in a replication-defective adenovirus vaccine to influenza-immune mice would induce longer-lived protection against lethal influenza infection. Accordingly, mice were infected with a low dose of influenza virus A/HK/X31 (X31) 19 and then either left unboosted or boosted 1 month later with replicationdefective adenovirus alone (control Ad), Ad-NP, or Ad-NP-4-1BBL ( Figure 1a) . We chose a vector dose of 10 6 pfu per mouse, which is 100-fold lower than the optimum dose required for maximal NP 366-374 -specific T-cell expansion with Ad-NP alone during priming. 15 Circulating memory CD8 T cells were followed in the blood for 9-11 months in two separate cohorts of mice, followed by influenza challenge. Inclusion of 4-1BBL in the vector dramatically enhanced the expansion of circulating NP 366-374 -specific CD8 T cells, which reached a maximum of 30% of circulating CD8 T cells by day 7, before declining over the next few weeks, and stabilizing at B10% of the CD8 T-cell population between day 60 and 120 ( Figure 1b,c) . Remarkably, this stable population of circulating CD8 memory cells persisted to at least 300 days. Similar results were recapitulated in the spleen for at least 7 months, where there was not only a higher frequency of NP 366-374 -specific memory cells in the circulating CD8 T-cell pool, but also an increase in the absolute number in Ad-NP-4-1BBL compared with Ad-NP or control-boosted groups ( Figure  1d ). At this low vector dose, the response to Ad-NP was only marginally higher than that of control Ad-boosted or unboosted mice (Figure 1b) .
To test the protective efficacy of Ad-NP-4-1BBL treatment, mice were challenged with a lethal dose of influenza A/PR8 (PR8) at 9-11 months post-boost. PR8 shares the same NP epitope as the initial priming X31 strain but contains different HA and NA proteins (PR8 is H1N1, whereas X31 is H3N2), thereby allowing us to assess protection from CD8 T-cell immunity without the interference of neutralizing antibody responses. 19 Mice pre-treated with Ad-NP-4-1BBL were protected from influenza-mediated weight loss and the majority survived challenge, whereas Ad-NP boosting offered a much smaller survival advantage over controls (Figure 1e,f) . There were no signs of splenomegaly or liver toxicity as measured by alanine transaminase levels in the serum (data not shown), suggesting that the localized 4-1BBL administration avoids the pathological effects that have been associated with systemic administration of anti-4-1BB agonistic antibody. 20 
4-1BBL-induced circulating memory cells have characteristics of long-lived effectors
Circulating memory T cells can be characterized as central memory (Tcm) or effector memory (Tem) based on their migration patterns and functional properties. Tcm are identified by high expression of CD62L and CCR7, and are more quiescent with greater proliferative potential upon reactivation. In contrast, Tem, which lack CD62L and CCR7, patrol the circulation and rapidly respond to antigen reencounter through IFNg and TNFa production. 21, 22 We therefore evaluated the circulating memory T cells for CD62L as well as for CD127, the IL-7Ra chain, to distinguish memory T cells from terminally differentiated effectors. 23, 24 NP 366-374 -specific CD8 T cells from Ad-NP-4-1BBL-boosted mice showed delayed acquisition of CD62L compared with Ad-NP or control Ad-boosted or unboosted mice ( Figure  2a,b) . This difference was first apparent at 2 months post-boost in the blood and persisted until at least 10 months. This decrease in Tcm and increase in Tem compartments was similarly observed in lymphoid organs, including the spleen (Figure 2c,d ) and dLN (data not shown). The delayed acquisition of CD62L by the Ad-NP-4-1BBL-boosted T cells was not accompanied by lower CD127 expression (Figure 2a,c) and therefore not a result of expanded terminally differentiated effectors.
The T-box transcription factors T-bet and Eomesodermin (Eomes) are key drivers of CD8 T-cell lineage differentiation. The higher expression of T-bet or Eomes is associated with effector-like or memory-like phenotypes, respectively. 25 Consistent with the effector-like nature of the memory CD8 T cells, the Ad-NP-4-1BBL boost induced higher T-bet expression early (day 7 post-boost, Figure 2e ), and lower Eomes between day 30 and 60 ( Figure 2f ) compared with Ad-NP in the spleen. The transcription factor T-cell factor 1 (TCF-1) is induced downstream of the canonical Wnt pathway, and regulates memory CD8 T-cell differentiation and longevity, partially through the induction of Eomes. 26 Splenic memory T cells from Ad-NP-4-1BBL-boosted mice have lower TCF-1 expression early post-boost (day 7, Figure 2g ). This effector-like transcriptional profile after 4-1BB stimulation appears to be a characteristic of secondary immunization, as T cells induced during primary immunization with Ad-NP or Ad-NP-4-1BBL were similar with respect to T-bet and Eomes profiles (data not shown). Differences in TCF-1 and T-bet were noted early (day 7) post-boost and thus are likely associated with memory programming rather than differences in the proportions of Tcm and Tem, which were not different at day 7 in the spleen when CD62L expression was very low in both Ad-NP and Ad-NP-4-1BBL-boosted groups (data not shown). By 6 months postboost, there is no longer a measureable difference in expression of these transcription factors between Ad-NP and Ad-NP-4-1BBL boosted NP-specific CD8 T cells, whereas Tcm and Tem frequency differences persist (Figure 2c-g) .
Consistent with the more effector-like memory phenotype, Ad-NP-4-1BBL boosting induced a significantly higher frequency, but not mean fluorescence intensity (MFI), of IFNgproducing CD8 T cells, as determined by ex vivo restimulation with the NP 366-374 peptide, even at 10 months post-boost when Ad-NP no longer differed substantially from controls ( Figure  3a,b) . Similar results were seen with TNFa and CD107a, with the latter showing a significantly higher MFI in Ad-NP-4-1BBL-boosted CD8 T cells. Ad-NP-4-1BBL-boosted mice also had more polyfunctional memory CD8 T cells, with a higher frequency of triple and quadruple producers of IFNg, TNFa, CD107a, and IL-2 in the blood (Figure 3c Trm are important mediators of protective immunity to influenza virus. 8, 10 Therefore, we investigated whether the local introduction of 4-1BBL with antigen through i.n. immunization impacted T cells in the lung. Intravascular infusion of labeled anti-CD8 antibody before euthanasia was used to distinguish vascular from parenchymal T cells that reside within the lung tissue ( Figure 4a) . 28 Much like the circulating response characterized in the blood and spleen, there was a dramatic augmentation in the initial expansion of NP 366-374 -specific CD8 T cells in the lung tissue parenchyma that peaked at day 7, and declined by day 60 to form a stable population that persisted to at least 7 months post-Ad-NP-4-1BBL boost (Figure 4a,b) . This occurred at a dose where the response induced by Ad-NP alone diminished within the first 60 days. Whereas NP 366-374 -specific cells made up the majority of the CD8 T cells within the lung tissue at their peak (day 7 postboost) in both Ad-NP and Ad-NP-4-1BBL-treated mice, the low numbers of CD8 T cells that remained in the lung at 7 months after Ad-NP boost contained few that were NP 366-374 -specific ( Figure 4c ). This was in contrast to Ad-NP-4-1BBL-boosted mice, where the stable population of Trm was largely NP 366-374 specific. These persistent lung parenchymal NPspecific T cells from the Ad-NP-4-1BBL-boosted mice
þ Trm have previously been identified in the lung, 29 whereas CD103 À CD69 þ Trm have been reported in the lamina propria, secondary lymphoid organs, and thymus. 7 Both these populations expressed low T-bet, Eomes, and CD127, as well as high 
À , and lung vascular memory CD8 T cells. Data were pooled from two separate experiments per time point with n ¼ 3 per group per experiment (mean±s.e.m.). NS not significant, *Po0.05, **Po0.005, ***Po0.0005, ****Po0.00005 (two-way ANOVA test). lung-homing CD49a compared with lung vascular memory populations (Figure 4e) , as previously reported for lung Trm. 28, [30] [31] [32] [33] We also observed lower TCF-1 expression in the lung NP-specific Trm. The CD103 À CD69 À population had an intermediate phenotype between the vascular and the CD69 þ parenchymal populations for many of these markers. Thus, stimulating 4-1BB directly in the respiratory tract induces a robust enlargement of the Trm population over control Ad-NP immunization, and this effect persists to at least 210 days postboost.
Ad-NP-4-1BBL acts directly on the CD8 T cells to induce expansion in local and systemic tissue compartments
To determine if 4-1BB was acting directly on the CD8 T cells or through another cell type, we used mixed bone marrow (BM) chimeras in which lethally irradiated mice were reconstituted with a 1:1 mix of 4-1BB þ / þ and 4-1BB À / À BM. Blood was monitored for degree of chimerism at 3 months postreconstitution, followed by priming with influenza A/X31. One month later, mice were given Ad-NP-4-1BBL by the i.n. route ( Figure 5a ). Before infection, the ratio of 4-1BB þ / þ to 4-1BB À / À CD8 T cells was B1:1 ( Figure 5b,c) . At 27 days after infection with X31, there was already a 3-to 4-fold advantage of 4-1BB þ / þ over 4-1BB À / À NP 366-374 -specific CD8 T cells in the blood, whereas the non-NP-specific CD8 T-cell compartment remained at the 1:1 ratio of the initial reconstitution (Figure 5c,d ). These data recapitulate previous studies on the role of 4-1BB/4-1BBL in maintaining the circulating CD8 T-cell memory pool.
14 At day 7 post-Ad-NP-4-1BBL boost (the peak response), the NP 366-374 -specific CD8 T cells were almost exclusively from the 4-1BB þ / þ donor in the lung parenchyma, lung vasculature, dLN, and spleen (Figure 5e,f) , and this dichotomy persisted out to day 50 post-boost (Figure 5g) . Thus the effects of 4-1BBL on the circulating and the lung-resident NP-specific memory CD8 T-cell populations are completely dependent on direct (intrinsic) effects of 4-1BB on the CD8 T cells.
Ad-NP-4-1BBL induces greater IL-7Ra (CD127) expression on memory CD8 T cells, which may contribute to the longevity of the response
We next asked if 4-1BB stimulation leads to long-lived memory T cells through effects on cytokine receptors associated with T-cell survival, memory commitment, and maintenance, including CD25 (IL-2Ra) and CD122 (IL-2Rb) and CD127
(the IL-7Ra subunit). CD25 and CD122, although present, did not show consistent differences between the Ad-NP and Ad-NP-4-1BBL groups (data not shown). However, Ad-NP-4-1BBL-boosted mice exhibited a higher frequency of CD127 þ NP 366-374 -specific memory CD8 T cells in the lung parenchyma but not lung vasculature compared with Ad-NP-boosted mice as early as day 7 post-boost, with similar results in the dLN. Modest frequency differences persisted in the spleen at day 30 ( Figure 6a,b) , but were no longer apparent by day 60 in any of the tissues examined (data not shown). Of note, the NP-specific CD8 T cells from the 4-1BBL-boosted group expressed higher CD127 at the per cell level from day 30 (Figure 6c ) to at least 6 months post-boost (Figure 6d,e) . MFI of CD127 was examined on total lung tissue at this time point instead of separated into lung parenchymal and vascular compartments because there were very few memory CD8 T cells left in the lung tissue in the Ad-NP group late in the boost response. The higher frequency and per cell expression of CD127 was specific to 4-1BB stimulation in the secondary response as mice given Ad-NP or Ad-NP-4-1BBL i.n. as a primary immunization did not exhibit this difference (data not shown).
To test the importance of IL7Ra induction in the boost phase, we used an anti-CD127 blocking antibody (Figure 6f) . IL-7R blockade at days 0 and 2 post-boost decreased the number of NP-specific memory T cells in the spleen by a similar proportion, regardless of whether the boost contained Ad-NP or Ad-NP-4-1BBL (Figure 6g ), consistent with a critical role for IL-7Ra in general. However, the lung Trm population was not affected by IL-7R blockade (data not shown). Whether this is because the systemic antibody does not effectively penetrate the lung parenchyma to block IL-7R or whether IL-7R is dispensable for the Trm cannot be distinguished in this experiment. Thus, 4-1BBL in the boost phase induces a sustained elevation of IL-7Ra levels on the NP-specific CD8 memory T cells, which may contribute to their increased persistence; however, it is difficult to ascertain the significance of this increase as IL-7R is critical for the memory response regardless of inclusion of 4-1BBL in the boost.
Delivery of 4-1BBL directly into the airways is required for the lung-resident memory response
We next asked whether existing CD8 Trm populations in the lung can be boosted by a systemic administration of 4-1BBL. Primary infection with low-dose X31 i.n. induced a small number of lung parenchymal NP 366-374 -specific memory CD8 T cells, which remained stable between days 30 and 70 postinfection in the tissue (Figure 7a,b) . Mice were boosted at 30 days after the i.n. prime with Ad-NP or Ad-NP-4-1BBL by either the i.n. or the i.p. route ( Figure 7c ). As expected, by day 7 the systemic i.p. boost had resulted in a much greater peak NP 366-374 -specific memory CD8 T-cell response in the spleen compared with i.n. administration (Figure 7d) . However, i.p. boost did not result in efficient accumulation of memory CD8 T cells in the lung, despite i.n. priming immunization. Importantly, systemic delivery of Ad-NP-4-1BBL did not significantly increase the number of NP 366-374 -specific CD8 T cells in the lung compared with Ad-NP alone. Thus, local delivery of the 4-1BBL-containing vector is required for lung-resident Trm accumulation in response to 4-1BBL during the boost phase.
Expansion of Trm during boosting is dependent on recruitment of T cells into the lung
The increase in Trm following intranasal boost with Ad-NP-4-1BBL could be due to expansion of existing memory T cells in the lung or recruitment of new effector T cells into the Trm pool. To distinguish these possibilities, we treated influenzaprimed mice daily by i.p. injection of either PBS or the immunomodulatory drug FTY720 during the boost phase (Figure 7e) . FTY720 causes internalization of the sphingosine 1-phosphate receptor resulting in the sequestration of lymphocytes within lymph nodes, thereby preventing lymphocytes from entering the circulation. 34 Thus, any CD8 memory T-cell expansion within the lung would be a result of 4-1BBL acting on populations already present in the lung before adenoviral boost. As expected, FTY720 treatment caused an increase of NP 366-374 -specific memory CD8 T cells within the dLN (data not shown), and a decrease in the blood (Figure 7f ) and spleen (data not shown). Without T cells trafficking into the lungs, there was a significant reduction of NP-specific cells in the tissue parenchyma after Ad-NP-4-1BBL boost (Figure 7g) , reducing the size of the Trm pool to a level comparable to the Ad-NP control boost. Interestingly, Ad-NP boost was not affected by FTY720 treatment. Furthermore, FTY720 did not affect the frequency of NP-specific CD8 T cells in the lung. These data suggest that the enhancement of Trm cells in the lung through local 4-1BB stimulation relies on recruitment of additional antigen-specific cells from the circulation.
The endogenous 4-1BB/4-1BBL pathway is critical for the formation or maintenance of the lung-resident CD8 population during primary influenza infection
Having established that a supraphysiological dose of 4-1BBL can locally augment the pre-existing NP-specific Trm population in the lung, we next asked whether the endogenous 4-1BB costimulatory pathway also plays a role in the establishment of the lung Trm population during primary influenza infection. To test the role of endogenous 4-1BB signaling in Trm induction, we again used 4-1BB þ / þ :4-1BB À / À mixed BM chimeras (Figure 8a) . After reconstitution, mice were infected i.n. with a low dose of X31 and killed 1 month later to study lung-resident populations. Late after primary infection, the NP 366-374 -specific CD8 T cells were almost exclusively from the 4-1BB þ / þ donor. This dichotomy was not nearly as striking in the dLN or spleen (Figure 8b-d) . Similar results were obtained for the immunodominant influenza PA 224-233 epitope (data not shown). This endogenous 4-1BB þ / þ lung-resident memory pool comprised the conventional Trm-associated Figure 8e) . The lack of 4-1BB À / À memory CD8 T cells specifically in the lung tissue suggests that the 4-1BB/4-1BBL pathway acts directly on Trm and is critical for the establishment or maintenance of Trm during influenza infection.
DISCUSSION
Tissue-resident memory T cells provide a vital defense against infection at barrier and mucosal surfaces. 6, 7 Here we have shown that both supraphysiological as well as endogenous 4-1BB provide an indispensable signal for influenza virusspecific CD8 Trm. Using 4-1BB þ / þ : 4-1BB À / À mixed BM chimeras, we show that there is an almost complete failure of 4-1BB À / À T cells to contribute to the lung-resident CD8 Trm pool after primary i.n. influenza infection. Moreover, administering 4-1BBL in a local boost with antigen in the same vector can induce a highly stable population of memory CD8 T cells that persists for almost a year and protects mice from lethal influenza challenge. This long-lived memory T-cell population includes a circulating effector memory subset that expresses higher levels of IL-7R compared with cells boosted without 4-1BBL as well as a robust Trm population, consisting of both CD103 þ and CD103 À subsets. The accumulation of Trm in response to 4-1BBL is completely dependent on 4-1BB expression on the CD8 T cells (Figure 5) , local delivery of 4-1BBL into the airways of the mouse (Figure 7c,d) , recruitment of antigen-specific CD8 T cells from the circulation (Figure 7e-g ), and inclusion of Ag and 4-1BBL in the same vector (data not shown).
The effect of local 4-1BBL administration on the Trm pool requires that new effector cells are recruited to the lung (Figure  7e-g) . Previous work has shown that 4-1BB/4-1BBL interactions are dispensable for controlling the number of NP-specific CD8 T cells observed in the lung at days 9-10 of a primary infection with influenza A/X31 as used here. 35 Thus, it seems unlikely that 4-1BBL is involved in recruitment of the effectors to the lung per se, but rather in the establishment or maintenance of the Trm once these cells reach the tissue. Effects of exogenous 4-1BB stimulation on T-cell accumulation are largely due to effects on survival rather than on the initial rate of division. 36 Consistently, we did not observe significant increases in bromodeoxyuridine uptake by CD8 T cells boosted with or without 4-1BBL (data not shown). 4-1BB stimulation has been shown to impact multiple survival pathways, through NF-kB-mediated upregulation of the anti-apoptotic genes Bcl-xL and Bfl1 (ref. 37 ) and TRAF1-Erk-dependent downmodulation of the proapoptotic Bim. 36, 38 Thus it is likely that 4-1BB mediates several pro-survival signals to enhance the Trm population. These survival signals may be important in keeping the antigen-specific T cells alive in the lung as they differentiate into Trm and/or they may be important in the maintenance of the already established Trm cells. Regardless, it is clear that without 4-1BB, the Trm are virtually absent by day 30 post priming.
The effect of endogenous 4-1BB was much more striking on the lung Trm population, than the circulating effector memory population observed in the spleen at day 30 after primary influenza infection. Previous work showed that 4-1BBL has about a 2-fold effect on the Tem population observed in the spleen at day 38 post-prime.
14 However, in the current studies, this small effect did not reach statistical significance (Figure 8c) . In contrast, 4-1BB þ / þ cells almost exclusively populated the lung Trm pool (Figure 8c) . On the other hand, when supraphysiological 4-1BBL signals are given in the boost using the Ad-NP-4-1BBL vector, effects on Tem and Trm were both dramatic. This is likely because 4-1BB is more highly expressed upon reactivation of primed T cells than on naive T cells 16 and because the amount of endogenous 4-1BBL is much lower than the amount achieved with the adenovirus vector.
Adenoviruses can enter cells that express the coxsackievirus and adenovirus receptor, such as airway epithelial cells, 39 but are also known to infect monocytes and dendritic cells by a coxsackievirus and adenovirus receptor-independent pathway. 40, 41 Previous work showed that Ad-4-1BBL induces 4-1BBL expression on both CD45
À and CD45 þ cells in the lung, with the former showing greater expression 35 and no detectable expression in the draining LN, suggesting a largely local effect. Given that the airway epithelial cells are by far the most abundant targets for adenoviral infection in the lung and the very low viral vector dose administered in our model, it is plausible that the NP and 4-1BBL delivered by the Ad vector are presented to the T cells by epithelial cells to induce local effects on the Trm or in the recruited Trm precursors. The ability of 4-1BBL to impact T cell responses through non-professional antigen presenting cells is perhaps not surprising given the CD28-independence of the 4-1BB signal. 42 The source of endogenous 4-1BBL for driving expansion of the Trm population during primary influenza infection remains to be determined. However, 4-1BBL is expressed on CD11c hi
CD11b
hi MHC II þ cells in the lung of influenza infected mice 43 and 4-1BBL mRNA is also present albeit at low levels in the lungs of unimmunized mice as measured by polymerase chain reaction. 35 Although anti-4-1BB agonist antibodies have been administered systemically to induce expansion of T cells, 44, 45 this is associated with expansion of endogenous CD4 and CD8 effector memory cells independent of immunization 46 and leads to immunopathology. 20 In contrast, by delivering 4-1BBL in the same vector as antigen straight into the airways, we did not observe splenomegaly or increased liver enzyme activity that is observed with systemic anti-4-1BB administration. 20 This is likely because the low-dose local delivery of 4-1BBL with antigen preferentially targets the antigen-specific response to the immunogen.
IL-7R has been identified as necessary but not sufficient for the formation of memory CD8 T cells in the context of viral infection. 47 In the present study, we identified greater IL-7R expression, both in frequency at early time points and in per cell expression late in the response in 4-1BBL-boosted circulating and lung-resident memory CD8 T cells. IL-7R expression is correlated with the pro-survival molecule Bcl-2 and identifies long-lived memory precursor cells. 23 However, it is difficult determine the importance of the relatively small increase in per cell level of expression of the IL-7 receptor for the 4-1BBL-mediated effects, given that IL-7R is necessary for memory CD8 T cell formation in general during viral infection 47 and blocking IL-7R during the boost similarly attenuated memory formation in both the Ad-NP and Ad-NP-4-1BBL groups. Antigen presentation can be detected within draining lymph nodes for at least 40 days post-immunization with replication-defective adenoviruses, with CD8 T cells exhibiting signs of chronic activation even out to 60 days. 27 Thus the prolonged expression of NP and 4-1BBL in the airways may be an important component of the dramatically enlarged Trm population and the long-lived protective response. Indeed, prolonged antigen stimulation has been associated with Tem differentiation. 48 Furthermore, prolonged cognate antigen stimulation has been implicated in maintaining the expression of the Trm marker CD103. 8 Despite the reported persistence of Ad-induced antigen presentation for B2 months, 4-1BBL administration in the present study induces Trm for at least 210 days postboost and protection out to at least a year. It is possible that durable changes induced by 4-1BBL are either programmed during the period that the adenovirus delivered genes are expressed, or potentially that the initial response is maintained by the lower level of endogenously expressed 4-1BBL. 35 Indeed, in earlier adoptive transfer studies of circulating CD8 T-cell memory, 4-1BBL was found to be dispensable for priming, but required for maintenance of CD8 memory T cells. 18 It is also important to note that prolonged antigen-presentation by replication-defective adenovirus vectors at high doses can induce a CD8 T-cell phenotype consistent with partially exhausted Tem cells. 27 This was observed in our study as well. At higher dose of Ad-NP, we saw a loss in the ability of memory CD8 T cells to produce multiple cytokines (Figure 3d,e) . However, boosting with 4-1BBL induced a polyfunctional influenza-specific CD8 T-cell response at a much lower dose of Ad vector and antigen, potentially avoiding the exhaustive effect of high-dose persisting antigen.
In sum, we have shown that 4-1BB is critical on CD8 T cells for induction of a long-lived lung Trm population through endogenous as well as supraphysiological stimulation. This signal must be locally delivered and is critical in the induction of optimal T-cell responses within the lung for protective immunity against influenza infection. Although the inclusion of a self-molecule like 4-1BBL may not be a practical vaccine strategy, the upregulation of 4-1BBL and other TNFR-family ligands is an important factor to consider when developing adjuvants for future vaccines.
METHODS
Mice. C57BL/6 mice were purchased from Charles River Laboratories (St. Constant, Quebec, Canada). Both male and female mice were used for experiments, but were age-and sex-matched within each experiment. For BM chimera experiments, Thy1.1 (B6.PL-Thy1 a /CyJ) and CD45.1 (C57Bl/6-Ly5.1) mice were purchased from Jackson Laboratories (Bar Harbor, USA), with the latter bred in-house at the University of Toronto. 4-1BB À / À mice, bred on the C57BL/6 background were obtained from B. Kwon (Tulane University, New Orleans, LA) 49 and used as source of donor cells for BM chimeras. All mice were housed in sterile micro-isolator cages under specific pathogen-free conditions. Animal studies were approved by the University of Toronto Animal Care Committee in accordance with the regulations of the Canadian Council on Animal Care.
Viruses. Influenza A/HK/X31 and A/PR8 viruses were grown in eggs and their tissue culture infectious dose determined by infection of MDCK cells. 50 Mice (5-6 weeks of age) were immunized with 30 ml of diluted virus at the indicated doses by i.n. infection while anaesthetized with isofluorane. For PR8 infections, mice were monitored closely with daily weights taken and were killed when moribund. Replicationdefective adenovirus 5 expressing influenza NP in the E1 region were kindly provided by J. Bramson (McMaster University, Hamilton, ON, Canada). The NP gene was derived from influenza A/PR8 GenBank: J02147.1. Adenovirus expressing NP in E3 and 4-1BBL in E1 were generated as previously published. 15 Immunizations of mice with adenovirus were performed at the indicated doses and schedule by i.n. or i.p. injections as indicated.
Tissue harvest and processing. Mice were injected intravenously with 3 mg of anti-mouse CD8a (clone: 53-6.7) antibody conjugated to PE (eBioscience, San Diego, CA) or BV605 (BioLegend, San Diego, CA) and killed 10 min later. 28 Lung tissue was perfused with 10 ml of PBS to remove cells in the pulmonary vasculature, and then minced and digested in 100 units per ml of collagenase IV (Invitrogen, Carlsbad, CA) for 1 h at 371 in a shaker. Spleen (after RBC lysis) and dLN were mechanically disrupted and filtered through a 70 mM to create single cell suspensions. Blood was collected from the saphenous vein and treated with RBC lysis buffer.
Flow cytometry and intracellular cytokine staining. Influenza NP 366-374 -specific CD8 T cells were analyzed using MHC class I tetramers obtained from the National Institute for Allergy and Infectious Disease tetramer facility (Emory University, Atlanta, GA). For intracellular cytokine staining, lung and spleen samples were restimulated ex vivo with 1 mM of the MHC I-restricted NP peptide for 6 h with GolgiStop (BD Pharmingen, San Jose, CA) at 37 1C. Cells were surfaced stained, fixed, permeabilized, and stained intracellularly for the appropriate cytokines. Unstimulated samples (no peptide) were used as negative controls. Samples were analyzed using LSRFortessa (BD Biosciences), and FlowJo (TreeStar, Ashland, OR) software.
Antibodies. The antibodies used in this study are as follows: antimouse CD8a (clone: 53-6.7) (eBioscience), anti-mouse CD3e (clone: 145-2C11) (eBioscience, BioLegend), anti-mouse Thy1.1 (clone: HIS51) (eBioscience), anti-mouse CD62L (clone: MEL-14) (eBioscience), anti-mouse CD127 (clone: A7R34) (eBioscience), antimouse IFNg (clone: XMG1.2) (eBioscience), anti-mouse TNFa (clone: MP6-XT22) (BD Pharmingen), anti-mouse IL-2 (clone: JES6-5H4) (eBioscience), anti-mouse CD107a (clone: 1D4B) (eBioscience), antimouse T-bet (clone: 4B10) (eBioscience), anti-mouse Eomesodermin (clone: Dan11mag) (eBioscience), rabbit anti-mouse TCF-1 (clone: MA5-14965) from Thermo Fisher (Waltham, MA) with labeled secondary donkey anti-rabbit (Thermo Fisher), anti-mouse CD69 (clone: H1.2F3) (eBioscience), anti-mouse CD103 (clone: 2E7) (eBioscience), anti-mouse CD49a (clone: Ha31/8) (BD Pharmingen), and fixable viability dye (eBioscience). In vivo IL-7R blockade was performed with i.p. injections of 400 mg per dose per mouse of anti-CD127 monoclonal antibody (clone: A7R34) at two doses, 2 days apart in the indicated immunization schedule. The hybridoma was kindly provided by C. Paige (University Health Network, Toronto, ON, Canada).
Mixed bone marrow chimeras. Bone marrow was obtained from the femur and tibia of wildtype Thy1.
À / À mice and transferred at a 1:1 ratio into host Thy1.2 þ / þ CD45.1 þ / þ 4-1BB þ / þ mice that were lethally irradiated with two doses of 550 rad. 2.5 Â 10 6 cells of each donor type were mixed and transferred in a total of 200 ml by intravenous tail vein injection. Reconstituted chimeric mice received water supplemented with 2 mg ml -1 neomycin sulfate (Bio-Shop, Burlington, ON, Canada) during the first 2 weeks, and were rested for a total of 90 days before chimerism was checked. They were then immunized according to the indicated schedules. Statistics. Statics were performed using GraphPad Prism 6 (San Diego, CA), with the specific test performed as indicated in the figure legends.
